ORI Capital


ORI Capital is a venture capital firm founded in 2015, focusing on investing in innovative early-stage biotech companies globally. The firm targets areas such as diagnostics, drug delivery, and therapeutics, particularly in disease areas with high mortality rates like cancer, cardiovascular, and neurodegenerative diseases. ORI Capital aims to be financially successful for its investors while being socially impactful to patients worldwide.

ORI Capital

ORI Capital

4727-34, Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong


Portfolio

Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. The company aims to utilize Induced Pluripotent Stem Cell (iPS) derived pancreatic islets to cure insulin dependent diabetes.

#Biotechnology

World’s first fully humanized antibodies selection platform generating disease-modifying drugs.

#Biotechnology

World’s leading gene therapy company targeting multiple diseases with limited or no existing treatment.

#Gene Therapy

It is the only company to date that can deliver drugs to pancreatic tumors using its innovative delivery device.

#Biotechnology

The leading oncolytic virus company in Phase 3 bladder cancer.

#Biotechnology


Key People

Founder & Senior Partner

Partner

Operating Partner

Director

Investment Associate

Approach-specific Scientist

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.